Thrivent Financial for Lutherans Sells 93,804 Shares of Enovis Corporation $ENOV

Thrivent Financial for Lutherans trimmed its holdings in shares of Enovis Corporation (NYSE:ENOV) by 43.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 119,825 shares of the company’s stock after selling 93,804 shares during the quarter. Thrivent Financial for Lutherans owned approximately 0.21% of Enovis worth $3,757,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in ENOV. Teacher Retirement System of Texas grew its position in shares of Enovis by 6.1% during the 2nd quarter. Teacher Retirement System of Texas now owns 8,664 shares of the company’s stock valued at $272,000 after acquiring an additional 495 shares during the period. Wedge Capital Management L L P NC lifted its position in Enovis by 0.3% during the second quarter. Wedge Capital Management L L P NC now owns 162,977 shares of the company’s stock valued at $5,111,000 after purchasing an additional 498 shares in the last quarter. Janney Montgomery Scott LLC grew its holdings in Enovis by 2.7% during the second quarter. Janney Montgomery Scott LLC now owns 22,375 shares of the company’s stock valued at $702,000 after purchasing an additional 593 shares during the period. California State Teachers Retirement System increased its position in Enovis by 1.2% in the second quarter. California State Teachers Retirement System now owns 51,713 shares of the company’s stock worth $1,622,000 after buying an additional 621 shares in the last quarter. Finally, Live Oak Investment Partners raised its stake in shares of Enovis by 2.5% in the second quarter. Live Oak Investment Partners now owns 26,352 shares of the company’s stock worth $826,000 after buying an additional 640 shares during the period. 98.45% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ENOV has been the subject of several analyst reports. Wells Fargo & Company increased their target price on shares of Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enovis in a research report on Wednesday, October 8th. Finally, Canaccord Genuity Group decreased their price objective on shares of Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a research report on Wednesday. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $49.83.

Insider Buying and Selling at Enovis

In other news, insider John Kleckner bought 2,468 shares of Enovis stock in a transaction dated Tuesday, November 25th. The shares were purchased at an average cost of $30.32 per share, with a total value of $74,829.76. Following the completion of the acquisition, the insider owned 12,302 shares of the company’s stock, valued at $372,996.64. This trade represents a 25.10% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Daniel A. Pryor sold 999 shares of the business’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total value of $27,172.80. The disclosure for this sale is available in the SEC filing. 2.70% of the stock is owned by insiders.

Enovis Trading Down 2.1%

ENOV stock opened at $26.75 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.22 and a quick ratio of 1.16. Enovis Corporation has a 1-year low of $25.47 and a 1-year high of $49.38. The business has a 50 day simple moving average of $29.70 and a two-hundred day simple moving average of $30.35. The company has a market capitalization of $1.53 billion, a price-to-earnings ratio of -1.13 and a beta of 1.52.

Enovis (NYSE:ENOV) last released its earnings results on Monday, January 8th. The company reported $0.59 EPS for the quarter. Enovis had a negative net margin of 61.22% and a positive return on equity of 7.79%. The firm had revenue of $383.81 million for the quarter. Research analysts anticipate that Enovis Corporation will post 2.79 EPS for the current fiscal year.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.